<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Sign Up
    May 18, 2024

    Upcoming Webinar: Targeted Protein Degradation - New Modalities and Design Technologies


    Targeted Protein Degradation - New Modalities and Design Technologies

    Join us for our upcoming webinar on targeted protein degradation. Scheduled for June 20, 2024, this event is set to bring together leading experts Bernhard Fasching, PhD, VP Chemistry at Monte Rosa Therapeutics, and Benedict Cross, PhD, CTO at PhoreMost Therapeutics.

    Together, they will explore promising new modalities gaining traction in drug discovery and unveil strategies and technologies aimed at targeting previously "undruggable" diseases. 

    This session is perfect for both seasoned researchers and newcomers to the field, offering insights that will enrich your understanding of drug discovery's latest advancements. Don’t miss this opportunity to engage with industry leaders and deepen your knowledge. Reserve your free seat now or register to receive a link to the on-demand recording and watch it at your convenience.

     Thursday, June 20, 2024, at 8:00 AM (PDT) 11:00 AM Eastern (EDT) 4:00 PM (BST)

    Register Now

    Featuring these leading scientists...


    Bernhard Fasching, PhD

    VP Chemistry, Monte Rosa Therapeutics

    Graduated from the University of Dortmund and the Max Planck Institute for Kohlenforschung in 2007 in Total Synthesis with Prof. Fuerstner followed by a Post-Doc experience at Memorial Sloan Kettering working on glycopeptide synthesis with Prof. Danishefsky. Ever since, he has been working on the discovery and development of novel pharmacologically active molecules and principles for Hoffmann-La Roche and for a number of biotech companies in the areas of neuroscience, oncology and rare diseases. He has successfully lead drug discovery programs, using medicinal chemistry to advance molecules to patients. More recently, he has put a focus on the creation of biotech platforms centered around novel modes of action such as molecular glue degraders. Currently he is the head of chemistry at Monte Rosa Therapeutics leading the medicinal chemistry teams in drug discovery as well as the platform group with the aim to understand and employ the molecular mechanisms of ternary com.


    Benedict Cross, PhD

    CTO,  PhoreMost Therapeutics

    The current Chief Technology Officer at PhoreMost, a drug discovery company based in Cambridge, UK. He is a pioneer in the use of programmed mini-protein perturbagens to uncover new drug targets and has applied this in the protein degradation field in particular. Ben’s research interests are in protein biogenesis, proteostasis, TPD and functional genomic screening.


    Tag(s): CDD Blog , Webinars

    Other posts you might be interested in

    View All Posts
    CDD Blog
    8 min   June 13, 2024
    Drug Discovery Industry Roundup with Barry Bunin — June, 13 2024
    Read More
    CDD Vault Updates
    4 min   June 10, 2024
    CDD Vault Update (June 2024): Add a Title, Arbitrary Lines, Add/Remove Whiskers in Dose-response Plots, Request More Bioisostere Hits, and Indent Lists in ELN
    Read More
    CDD Vault Updates
    3 min   May 24, 2024
    CDD Vault Update (May 2024 #3): Resume Vault Session & Deep Learning Enhancements: More Hits, Persist Calculated Properties
    Read More